Effect of higher dose primaquine for the radical cure of Plasmodium vivax malaria in Indonesia: a systematic review and individual patient data meta-analysis

This systematic review and individual patient data meta-analysis of 1,797 patients in Indonesia demonstrates that a higher total primaquine dose of 7 mg/kg significantly reduces *Plasmodium vivax* relapse rates compared to the standard 3.5 mg/kg regimen, with only a moderate increase in gastrointestinal discomfort and rare clinically relevant haemolysis among patients with adequate G6PD activity.

The Gist

Imagine your body is a fortress under siege by an enemy called Plasmodium vivax, a type of malaria parasite. This enemy is tricky. When you take medicine to kill the active soldiers (the parasites currently in your blood), the enemy has a secret backup plan: they hide in the "attic" of your liver as dormant spies called hypnozoites. Weeks or months later, these spies wake up, jump back into your bloodstream, and cause a new attack (a relapse).

To stop this, doctors use a special drug called Primaquine to clean out the attic and kill the spies before they can wake up. But here's the problem: for years in Indonesia, doctors were using a "low dose" of this drug because they were worried about side effects. It was like sending a small broom to sweep a massive attic—it might catch a few dust bunnies, but it often misses the big mess.

This new study is like a massive, high-tech investigation that gathered data from nearly 1,800 patients across Indonesia to answer one big question: Is it better to use a bigger broom (a higher dose) to sweep the attic cleaner, even if it's a little harder to hold?

The Big Discovery: The "Double Dose" Wins

The researchers found that doubling the dose of Primaquine (going from 3.5 mg/kg to 7 mg/kg) is a game-changer.

• The Analogy: Think of the low dose as a gentle rain that wets the roof but doesn't wash away the grime. The high dose is a powerful pressure washer.
• The Result: The high dose cut the rate of malaria coming back in half compared to the low dose. It didn't matter if the patient was in a high-risk area (like Papua) or a lower-risk area; the high dose was simply more effective at clearing the attic.

The Catch: The "Nausea" Factor

Every good thing has a trade-off. The study found that while the high dose was better at killing the malaria spies, it was a bit harder on the stomach.

• The Analogy: Imagine the high-dose drug is a very spicy curry. It gets the job done (kills the malaria), but it might make your tummy rumble or make you feel a bit queasy more often than the mild soup (low dose).
• The Reality: About 15% of people on the high dose felt some stomach discomfort, compared to fewer on the low dose. However, the researchers noted that if you take the medicine with food, it's like eating the spicy curry with a side of rice and yogurt—it calms the stomach down significantly.

The Safety Concern: The "Red Blood Cell" Risk

There was another worry: Primaquine can sometimes cause a reaction in people who lack a specific enzyme (called G6PD), leading to their red blood cells breaking apart (hemolysis). This is like the drug accidentally eating the fuel tanks of your body's delivery trucks.

• The Finding: The study looked at this very closely. They found that for people with normal or near-normal enzyme levels (which is almost everyone), the high dose was safe.
• The One Exception: There was one rare case of a woman with "intermediate" enzyme levels who had a significant drop in blood count. This is a crucial warning: You must test for this enzyme before giving the high dose. If you know the patient is safe, the high dose is a safe, powerful tool.

The Bottom Line for Indonesia

Indonesia is a huge country with different malaria risks in different places.

• In high-risk areas (like Papua): The "pressure washer" (high dose) is absolutely necessary because the attic is full of spies.
• In lower-risk areas: The high dose is still better, but the low dose might be "okay" if the risk of relapse is already low.

The Takeaway:
This study suggests that Indonesia should update its rules. Instead of being afraid of the "spicy curry," doctors should prescribe the high dose (7 mg/kg) to almost everyone, provided they check the patient's enzyme levels first and tell them to take it with food.

By doing this, they can sweep the attic clean, stop the malaria from coming back, and save thousands of people from getting sick again. It's a smarter, stronger strategy to finally win the war against this sneaky parasite.

Technical Summary

1. Problem Statement

Plasmodium vivax malaria remains a significant public health burden in Indonesia, characterized by diverse transmission patterns and relapse mechanisms driven by dormant liver-stage hypnozoites. Radical cure (elimination of hypnozoites) requires the administration of 8-aminoquinolines, primarily primaquine.

• Current Guideline: Indonesian national guidelines recommend a low total dose of 3.5 mg/kg over 14 days without routine Glucose-6-Phosphate Dehydrogenase (G6PD) testing.
• The Gap: A 2024 global meta-analysis suggested that a high total dose of 7 mg/kg could halve recurrence rates compared to 3.5 mg/kg. However, Indonesia's epidemiological heterogeneity (e.g., high relapse risk in Papua vs. lower risk in Sumatra) and operational challenges (lack of universal G6PD screening) create uncertainty regarding the optimal regimen. There was a lack of head-to-head, individual-level data comparing these regimens specifically within the Indonesian context.

2. Methodology

This study is a one-stage Individual Patient Data (IPD) meta-analysis and systematic review.

• Data Sources: A systematic search (Jan 1, 2000 – July 23, 2024) of MEDLINE, Embase, Web of Science, Scopus, and Cochrane Library identified 10 eligible studies conducted in Indonesia.
• Inclusion: Seven studies provided IPD, encompassing 1,797 patients with acute uncomplicated P. vivax malaria.
• Exclusion Criteria: Patients with severe malaria, pregnancy, mixed infections, or those receiving additional antimalarials post-schizonticidal treatment were excluded.
• Statistical Approach:
  • Efficacy: Modeled using a multivariable Cox proportional hazards model to estimate the time to first recurrence (Days 7–180). The model adjusted for age, sex, baseline parasite density, and study site (stratified). A restricted cubic spline was used to model the non-linear dose-response relationship.
  • Tolerability: Modeled using multivariable Poisson regression for gastrointestinal (GI) discomfort (Days 5–7) and acute vomiting.
  • Safety: Modeled using multivariable linear regression for maximum hemoglobin drop (Days 1–14) and Poisson regression for clinical hemolysis (Hb drop ≥25% to <7 g/dL).
  • Bias Control: Causal Directed Acyclic Graphs (DAGs) guided covariate selection. Negative control analyses (using P. falciparum reinfection and body weight) were employed to detect residual confounding.

3. Key Contributions

• First Country-Specific IPD Meta-Analysis: This is the most comprehensive analysis to date of primaquine dosing specifically for Indonesia, moving beyond aggregate study-level data to patient-level granularity.
• Dose-Response Quantification: It provides precise estimates of the causal relationship between weight-adjusted primaquine doses and clinical outcomes (efficacy, tolerability, safety) across varied endemic settings.
• Subgroup Analysis: It specifically investigates effect modification by geographic origin (Papua vs. non-Papua) and G6PD status (specifically intermediate activity in females), addressing critical operational questions for national policy.

4. Key Results

A. Anti-Relapse Efficacy

• Dose Comparison: Compared to the low dose (3.5 mg/kg), the high total dose (7 mg/kg) reduced the rate of P. vivax recurrence over 6 months by approximately 50%.
  • Adjusted Hazard Ratio (AHR): 0.53 (95% CI: 0.45–0.63).
• Regional Consistency: The relative efficacy was consistent across regions (Papua and non-Papua). However, the absolute benefit varied due to differing baseline recurrence risks:
  • Papua: High baseline risk (Incidence Rate: 0.63/person-year). Number Needed to Benefit (NNB) to prevent one recurrence in 6 months: ~4 patients.
  • Non-Papua: Lower baseline risk (Incidence Rate: 0.31/person-year). NNB: ~12 patients.
• Dose Ceiling: Increasing the dose beyond 7 mg/kg showed uncertain additional efficacy due to wide confidence intervals.

B. Gastrointestinal Tolerability

• Daily Dose Impact: GI discomfort (vomiting, anorexia, diarrhea) on Days 5–7 increased with higher daily doses.
  • Adjusted Risk Ratio (ARR): 1.32 per 0.25 mg/kg/day increment (95% CI: 1.15–1.51).
• Timing: No significant increase in symptoms was observed on Day 0 or Days 1–2, suggesting symptoms are linked to cumulative daily exposure rather than immediate administration.

C. Hematological Safety

• Clinical Hemolysis: In 822 patients assessed (96% with G6PD activity ≥70%), only one patient developed clinically relevant hemolysis.
  • Case Details: A female with intermediate G6PD activity (37.4%) treated with a high daily dose (0.99 mg/kg) experienced a 41% Hb drop but recovered without transfusion.
• G6PD Interaction:
  • Females: Higher daily doses were associated with greater Hb drops in females with intermediate G6PD activity (30–69%).
  • Males: No significant association between lower G6PD activity and Hb drops was observed.
• Methemoglobinemia: Higher daily doses increased methemoglobin levels (prevalence of ≥10% was 25.5%), though this was generally asymptomatic and self-resolving.

5. Significance and Implications

• Policy Recommendation: The study supports the adoption of a high total dose of 7 mg/kg for radical cure in Indonesia, aligning with updated 2024 WHO guidelines. This dose effectively halves recurrence rates.
• Stratified Implementation:
  • Papua: Due to the high absolute risk of relapse, the high dose is critically important (NNB of 4).
  • Low-Risk Regions: While the high dose is more efficacious, the absolute benefit is lower. A tiered national strategy is proposed, prioritizing 7 mg/kg in high-transmission/relapse areas while considering lower doses in elimination-focused areas.
• Risk Mitigation:
  • G6PD Screening: Essential for safety, particularly for females with intermediate activity. The risk of severe hemolysis is low in patients with G6PD activity >30% but requires monitoring.
  • Adherence: To mitigate GI discomfort associated with higher daily doses (required to achieve 7 mg/kg in 7 days vs. 14 days), co-administration with food is recommended.
• Conclusion: The study provides robust evidence that increasing the total primaquine dose to 7 mg/kg is safe and significantly more effective than the current 3.5 mg/kg regimen, provided that G6PD screening and adherence support (e.g., taking with food) are implemented. Future efforts should focus on optimizing delivery and adherence rather than testing doses higher than 7 mg/kg.